Clinical trial
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That…
NCT00005848 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005848 |
|---|---|
| Title | R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy |
| Official title | Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | chemotherapy, tipifarnib |
| Enrollment | 7 |
| Start date | Apr 1, 2000 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Mar 16, 2004 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: